

Haematologica  
HAEMATOL/2016/151860  
Version 2

Autotransplant with and without induction chemotherapy in older multiple myeloma patients: long-term outcome of a randomized trial

Christian Straka, Peter Liebisch, Hans Salwender, Burkhard Hennemann, Bernd Metzner, Stefan Knop, Sigrid Adler-Reichel, Christian Gerecke, Hannes Wandt, Martin Bentz, Tim Hendrik Bruemmendorf, Marcus Hentrich, Michael Pfreundschuh, Hans-Heinrich Wolf, Orhan Sezer, Ralf Bargou, Wolfram Jung, Lorenz Trümper, Bernd Hertenstein, Else Heidemann, Helga Bernhard, Nicola Lang, Norbert Frickhofen, Holger Hebart, Ralf Schmidmaier, Andreas Sandermann, Tobias Dechow, Albrecht Reichle, Brigitte Schnabel, Kerstin Schäfer-Eckart, Christian Langer, Martin Gramatzki, Axel Hinke, Bertold Emmerich, and Hermann Einsele

Collaborative Groups: DSMM (Deutsche Studiengruppe Multiples Myelom)

Disclosures: Conflict-of-interest disclosure: T.B. has received documentation fee within the study. R.B. has received personal fee from Amgen, Novartis and Astra Zeneca. H. S. has received grant support from Chugai. R.S. has received personal fees from Roche and Amgen, non-financial support from Celgene, Amgen, Alexion and Lilly. C.L. has received grant support from ElseKröner-Fresenius Stiftung. H.E. has received grant support from Celgene, Janssen and Novartis. The remaining authors declare no competing financial interests.

Contributions: Contributions: C.S. was the principal investigator, and was involved in the original idea and design of the study, writing the protocol, analyzing and interpreting the data, and writing the manuscript. A.H. planned and performed the statistical analyses. P.L. and C.L. performed the cytogenetic analyses. All authors were involved in patient recruitment and reviewed and approved the paper.